Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

INFOGRAPHIC: A US biotech IPO surge? Data are mixed

This article was originally published in Scrip

Executive Summary

Many people argue that the surge in initial public offerings by biotechnology companies suggests a bubble in danger of imminent explosion, but is the industry's IPO market really surging? It depends on how you interpret the numbers related to first-time stock offerings so far in 2014 versus 2015.

You may also be interested in...



VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs

During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.

Immuno-Oncology Data Drive Deal Dollars Higher

Immuno-oncology deals command relatively high values, but transaction volumes are increasing annually at a steady pace, not skyrocketing despite intense interest in the field as big pharma companies remain selective IO dealmakers based on the strength of early-stage data.

ARCH Cites Stability Of Long-Term Investors In Raising $3bn Fund

ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups. 

Latest News
UsernamePublicRestriction

Register

SC029125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel